Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio, Inc. (Nasdaq: ACET) announced its financial results for Q1 2022, reporting a net income of $4.6 million, compared to a net loss of $21.3 million in the same period last year. The company maintains a strong cash position with $277.9 million as of March 31, 2022. Significant operational highlights include the acceptance of interim data from the ADI-001 Phase 1 trial for oral presentation at the ASCO Annual Meeting and the granting of Fast Track Designation by the FDA for ADI-001 targeting Non-Hodgkin’s lymphoma. R&D expenses rose to $13.5 million.
Adicet Bio, Inc. (Nasdaq: ACET) presented promising preclinical data for ADI-001 during the ISCT Annual Meeting. The study highlighted ADI-001's strong in vitro and in vivo tumor growth inhibition across various human lymphoma cell lines, showcasing its adaptive and innate anti-tumor mechanisms. Notably, the non-gene-edited ADI-001 CAR T cells exhibited enhanced resilience against host-mediated clearance compared to gene-edited alternatives. ADI-001 is currently undergoing a Phase 1 clinical trial aimed at treating relapsed or refractory B-cell Non-Hodgkin’s lymphoma.
Adicet Bio, Inc. (NASDAQ: ACET), a clinical-stage biotechnology company, announced the granting of inducement awards on April 29, 2022, to four newly hired employees. The awards include non-qualified stock options to purchase a total of 62,000 shares at an exercise price of $14.74 per share, equal to the stock's closing price on that date. The vesting schedule allows for one-fourth of the shares to vest after one year, with the remainder vesting in monthly installments over three years. These awards were granted under Adicet's 2022 Inducement Plan, adopted in January 2022.
Adicet Bio, Inc. (NASDAQ: ACET) announced updated safety and efficacy data from the Phase 1 study of ADI-001 for treating relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022. The oral presentation, titled 'A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta T cells in adults with B-cell malignancies', is scheduled for June 6, 2022, at 8:00 AM CDT, featuring Sattva Neelapu, MD, from MD Anderson Cancer Center.
Adicet Bio (Nasdaq: ACET) has announced that the FDA granted Fast Track Designation to its lead program ADI-001, targeting CD20 for treating relapsed or refractory B-cell Non-Hodgkin’s lymphoma. This investigational therapy is currently in a Phase 1 study assessing its safety and tolerability. The Fast Track status accelerates its development, addressing an unmet need in adult NHL. CEO Chen Schor expressed optimism about ADI-001’s unique approach and anticipates further data release from the trial in early 2022.
Adicet Bio, Inc. (NASDAQ: ACET), a clinical-stage biotechnology firm, is advancing allogeneic gamma delta CAR T cell therapies for cancer. The company will participate in two investor conferences in April 2022. On April 14, CEO Chen Schor will join a panel at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference. Additionally, Adicet's management will conduct 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami, Florida on April 27, 2022. These events showcase Adicet's commitment to innovative cancer therapy development.
Adicet Bio, Inc. (NASDAQ: ACET) announced the granting of inducement awards on March 31, 2022, to two new employees as part of its 2022 Inducement Plan. The awards consist of non-qualified stock options to purchase a total of 36,000 shares at an exercise price of $19.97 per share, which reflects the closing price on the Grant Date. The options will vest progressively over four years, subject to continued employment. This plan was approved by an independent compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio, Inc. (ACET) reported positive interim findings in its Phase 1 study of ADI-001 for non-Hodgkin’s lymphoma, with complete responses observed at low dose levels. The company raised $94.2 million in net proceeds through a recent public offering, bolstering its financial position with $277.5 million in cash as of December 31, 2021. Despite a net loss of $62 million for 2021, which increased from $36.7 million in 2020, the company remains on track for key milestones in 2022, including additional clinical data expected soon.
Adicet Bio, Inc. (Nasdaq: ACET) announced the granting of inducement awards on February 28, 2022, to three new employees as part of its 2022 Inducement Plan. The awards include non-qualified stock options to purchase 87,800 shares at an exercise price of $13.08, based on the stock's closing price on the grant date. Options will vest over four years, contingent on continued employment. These awards fall outside stockholder-approved equity plans and were approved by the compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio, Inc. (NASDAQ: ACET) announced that CEO Chen Schor will participate in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on February 9, 2022, at 11:30 am ET. Investors can access the live audio webcast through the company's website, with an archived replay available for 30 days post-event. Adicet Bio is focused on developing allogeneic gamma delta CAR T cell therapies targeting cancer and other diseases, emphasizing durable anti-tumor immune responses.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
